Tissue inhibitor of metalloproteinase 4 in aqueous humor of patients with primary open angle glaucoma, pseudoexfoliation syndrome and pseudoexfoliative glaucoma and its role in proteolysis imbalance

BMC Ophthalmology

Volumn 13, Issue 1, 2013, Pages

  Fountoulakis, Nikitas ^a,b   Labiris, Georgios ^a,b   Aristeidou, Antonios ^a,b   Katsanos, Andreas ^c   Tentes, Ioannis ^a   Kortsaris, Alexandros ^a   Kozobolis, Vassilios P ^a,b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Eye Institute of Thrace   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Glaucoma; Metalloproteinases; Pseudoexfoliation; TIMP MMP ratios; TIMP4

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TISSUE INHIBITOR OF METALLOPROTEINASE-4;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; OPEN ANGLE GLAUCOMA; PROTEIN DEGRADATION; PSEUDOEXFOLIATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AQUEOUS HUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXFOLIATION SYNDROME; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROTEOLYSIS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84887368907     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-13-69     Document Type: Article

References (34)

1. Vaughn D, Asbury T, General Ophthalmology, Los Altos Calif.: Lange Medical Publications 1980 166 175
2. Pressures in the juxtacanalicular tissue and Schlemm's canal in monkeys. Maepea O, Bill A, Exp Eye Res 1992 54 879 883 10.1016/0014-4835(92)90151-H 1521580
3. What controls aqueous humour outflow resistance. Johnson M, Exp Eye Res 2006 82 4 545 557 10.1016/j.exer.2005.10.011 16386733 (Pubitemid 43122085)
4. The inner wall of Schlemm'scanal. Ethier CR, Exp Eye Res 2002 74 161 172 10.1006/exer.2002.1144 11950226 (Pubitemid 34948391)
5. Ultrastructural characteristics of glaucomatous trabecular meshwork. Potau JM, Canals M, Costa J, Merindano MD, Ruano D, Arch Soc Esp Oftalmol 2000 75 21 28 11151108
6. Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease. Lutjen-Drecoll E, Exp Eye Res 2005 81 1 4 10.1016/j.exer.2005.02.008 15978248 (Pubitemid 40840540)
7. Endothelin and its suspected role in the pathogenesis and possible treatment of glaucoma. Shoshani YZ, Harris A, Shoja MM, Rusia D, Siesky B, Arieli Y, Wirostko B, Curr Eye Res 2012 37 1 1 11 10.3109/02713683.2011.622849 22029631
8. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Sacca SC, Pascotto A, Camicione P, et al. Arch Ophthalmol 2005 123 458 463 10.1001/archopht.123.4.458 15824217 (Pubitemid 40489915)
9. Ocular and systemic pseudoexfoliation syndrome. Schlötzer-Schrehardt U, Naumann GO, Am J Ophthalmol 2006 141 5 921 937 10.1016/j.ajo.2006.01.047 16678509
10. Why is glaucoma associated with exfoliation syndrome? Ritch R, Schlötzer-Schrehardt U, Konstas AG, ProgRetin Eye Res 2003 22 3 253 275 (Pubitemid 38401056)
11. Matrix metalloproteinases. Nagase H, Woessner JF Jr, J Biol Chem 1999 274 21491 21494 10.1074/jbc.274.31.21491 10419448 (Pubitemid 29359963)
12. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. Woessner JF Jr, FASEB J 1991 5 8 2145 2154 1850705 (Pubitemid 21905847)
13. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Visse R, Nagase H, Circ Res 2003 92 8 827 839 10.1161/01.RES.0000070112.80711.3D 12730128 (Pubitemid 36542523)
14. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation: regulation by TIMP-2 and TIMP-3. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G, J Biol Chem 1996 271 17119 17123 10.1074/jbc.271.29.17119 8663332 (Pubitemid 26244261)
15. New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Clark AF, Invest Ophthalmol Vis Sci 1998 39 13 2514 2516 9856759 (Pubitemid 28558208)
16. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Bradley JM, Vranka J, Colvis CM, Conger DM, Alexander JP, Fisk AS, Samples JR, Acott TS, Invest Ophthalmol Vis Sci 1998 39 13 2649 2658 9856774 (Pubitemid 28558223)
17. Matrixmetalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Schlötzer-Schrehardt U, Lommatzsch J, Küchle M, Konstas AG, Naumann GO, Invest Ophthalmol Vis Sci 2003 44 3 1117 1125 10.1167/iovs.02-0365 12601038 (Pubitemid 36300758)
18. Matrix metalloproteinases and their tissue inhibitors in aqueous humor of patients with primary open-angle glaucoma, exfoliation syndrome, and exfoliation glaucoma. Määttä M, Tervahartiala T, Harju M, Airaksinen J, Autio-Harmainen H, Sorsa T, J Glaucoma 2005 14 1 64 69 10.1097/01.ijg.0000145812.39224.0a 15650607 (Pubitemid 40165495)
19. Involvement of inflammation, degradation, and apoptosis in a mouse model of glaucoma. Zhou X, Li F, Kong L, Tomita H, Li C, Cao W, JBiol Chem 2005 280 35 31240 31248 10.1074/jbc.M502641200 (Pubitemid 41291861)
20. European Glaucoma Society, Terminology and guidelines for Glaucoma Savona: Dogma S.r.l 3 2008
21. Control of matrix metalloproteinase catalytic activity. Ra HJ, Parks WC, Matrix Biol 2007 26 8 587 596 10.1016/j.matbio.2007.07.001 17669641 (Pubitemid 350180394)
22. Studies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen. Mackay AR, Hartzler JL, Pelina MD, Thorgeirsson UP, J BiolChem 1990 265 21929 21934 (Pubitemid 120014244)
23. Matrilysin-dependent elastolysis by human macrophages. Filippov S, Caras I, Murray R, Matrisian LM, Chapman HA Jr, Shapiro S, Weiss SJ, J Exp Med 2003 198 925 935 10.1084/jem.20030626 12963695 (Pubitemid 37152929)
24. Functional morphology of the trabecular meshwork in primate eyes. Lütjen-Drecoll E, Prog Retin Eye Res 1999 18 91 119 10.1016/S1350-9462(98) 00011-1 9920500 (Pubitemid 28457040)
25. Collagen degradation in glaucoma: will it gain a therapeutic value? La Rosa FA, Lee DA, Curr Opin Ophthalmol 2000 11 2 90 93 10.1097/00055735- 200004000-00004 10848226 (Pubitemid 30164027)
26. Unilateral exfoliation syndrome: conversion to bilateral exfoliation and to glaucoma-a prospective 10-year follow-up study. Puska PM, J Glaucoma 2002 11 517 524 10.1097/00061198-200212000-00012 12483098 (Pubitemid 36015112)
27. Recent developments in understanding the pathophysiology of elevated intraocular pressure. Tan JC, Peters DM, Kaufman PL, Curr Opin Ophthalmol 2006 17 2 168 174 16552252 (Pubitemid 43790813)
28. Transforming growth factor b2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Picht G, Welge-Luben U, Grehn F, Lutjen-Drecoll E, Graefes Arch Clin Exp Ophthalmol 2001 239 199 207 10.1007/s004170000252 11405069 (Pubitemid 32422026)
29. Hemodynamic evaluation of the posterior ciliary circulation in exfoliation syndrome and exfoliation glaucoma. Detorakis ET, Achtaropoulos AK, Drakonaki EE, Kozobolis VP, Graefes Arch Clin Exp Ophthalmol 2007 245 4 516 521 10.1007/s00417-006-0439-7 17111150 (Pubitemid 46477312)
30. Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology. Koskivirta I, Rahkonen O, Mäyränpää M, Pakkanen S, Husheem M, Sainio A, Hakovirta H, Laine J, Jokinen E, Vuorio E, Kovanen P, Järveläinen H, Histochem Cell Biol 2006 126 3 335 342 10.1007/s00418-006-0163-8 16521002
31. Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. Tummalapalli CM, Heath BJ, Tyagi SC, J Cell Biochem 2001 80 512 521 10.1002/1097-4644(20010315)80:4<512::AID- JCB1005>3.0.CO;2-N 11169735 (Pubitemid 32127466)
32. Tissue inhibitor of metalloproteinases-4 suppresses vascular smooth muscle cell migration and induces cell apoptosis. Guo YH, Gao W, Li Q, Li PF, Yao PY, Chen K, Life Sci 2004 75 20 2483 2493 10.1016/j.lfs.2004.07.007 15350823 (Pubitemid 39180052)
33. Matrix metalloproteinases and their inhibitors in the chamber angle of normal eyes and patients with primary open-angle glaucoma and exfoliation glaucoma. Rönkkö S, Rekonen P, Kaarniranta K, Puustjärvi T, Teräsvirta M, Uusitalo H, Graefes Arch Clin Exp Ophthalmol 2007 245 5 697 704 10.1007/s00417-006-0440-1 17028863 (Pubitemid 46951236)
34. Latanoprost therapy reduces the levels of TGFbeta1 and gelatinases in the aqueous humour of patients with exfoliative glaucoma. Konstas AG, Koliakos GG, Karabatsas CH, Liakos P, Schlötzer-Schrehardt U, Georgiadis N, Ritch R, Exp Eye Res 2006 82 2 319 322 10.1016/j.exer.2005.07.004 16115621 (Pubitemid 43122118)